This company listing is no longer active
Resumen de acción ALONC
Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de Oncodesign Société Anonyme
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €14.42 |
| 52 Week High | €14.64 |
| 52 Week Low | €7.83 |
| Beta | 1.33 |
| 1 Month Change | 0.14% |
| 3 Month Change | 1.55% |
| 1 Year Change | 57.25% |
| 3 Year Change | 63.12% |
| 5 Year Change | 25.39% |
| Change since IPO | 113.63% |
Noticias y actualizaciones recientes
Rentabilidad de los accionistas
| ALONC | FR Biotechs | Mercado FR | |
|---|---|---|---|
| 7D | 0% | -3.9% | -0.03% |
| 1Y | 57.3% | -11.7% | 1.8% |
Rentabilidad vs. Industria: ALONC exceeded the French Biotechs industry which returned -61% over the past year.
Rentabilidad vs. Mercado: ALONC exceeded the French Market which returned -9.6% over the past year.
Volatilidad de los precios
| ALONC volatility | |
|---|---|
| ALONC Average Weekly Movement | 1.7% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Precio estable de las acciones: ALONC has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: ALONC's weekly volatility has decreased from 8% to 2% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1995 | 236 | Philippe Genne | www.oncodesign.com |
Resumen de fundamentos de Oncodesign Société Anonyme
| Estadísticas fundamentales de ALONC | |
|---|---|
| Capitalización bursátil | €99.44m |
| Beneficios(TTM) | -€6.19m |
| Ingresos (TTM) | €32.67m |
3.0x
Ratio precio-ventas (PS)-16.1x
Ratio precio-beneficio (PE)¿Está ALONC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ALONC | |
|---|---|
| Ingresos | €32.67m |
| Coste de los ingresos | €17.60m |
| Beneficio bruto | €15.07m |
| Otros gastos | €21.26m |
| Beneficios | -€6.19m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.90 |
| Margen bruto | 46.14% |
| Margen de beneficio neto | -18.94% |
| Ratio deuda/patrimonio | 232.0% |
¿Cómo se ha desempeñado ALONC a largo plazo?
Ver rendimiento histórico y comparativa